

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/662,555	AYUKO ET AL.	
	Examiner	Art Unit	
	Ba K. Trinh	1625	

All Participants:

Status of Application: pending

(1) Ba K. Trinh.

(3) _____.

(2) Ms Kathy Dias.

(4) _____.

Date of Interview: 11/29/2004

Time: _____

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

1-20

Prior art documents discussed:

Part II.


SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

Authorization has been given to amend claims 18-19 and cancel claims 8-17 without prejudice so that the claimed invention is in condition for allowance.


BT okang

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


 (Examiner/SPE Signature)

 (Applicant/Applicant's Representative Signature – if appropriate)



5 in which Z¹ and Z² each independently represents a hydrogen or halogen atom and Z³ is a halogen atom.

18. A pharmaceutical composition comprising a carrier and one or more compounds according to claim 1, ~~8 or 13~~.

10 19. A method for treating proliferative diseases, microbial diseases or viral diseases comprising administering to a patient a therapeutically effective amount of a compound according to claim 1, ~~8 or 13~~.

20. A method according to claim 19 for inhibiting tumour growth.

BT
11/29/04